The Centre for Economic Development, Transport and the Environment of Northern Ostrobothnia (ELY Centre) has granted Innomentarium Oy €110,000 in EU co-funding to support the commercialization of the company’s imaging technology for international markets.
Since 2014, Innomentarium has been developing advanced soft-tissue imaging solutions that surpass the accuracy of conventional methods. The company’s technology enables the identification of extremely small, micrometer-scale structures in tissue, enhancing and supporting clinical diagnostics.
“We utilize modern image processing and image analysis methods, and we have developed our own machine learning and artificial intelligence algorithms to analyze image data and produce results,” says Angelos Fylakis, Head of the Product Development Team.
Commercialization Begins with Seed Quality Measurement
As its first market application, Innomentarium is launching solutions for quality measurement of forest and food seeds.
“Health technology is a slow-moving industry—bringing a product from idea to market often takes 5–10 years. The COVID-19 pandemic, healthcare system reform in Finland, and increasingly strict EU regulations have further slowed development,” says CEO Jouni Ihme.
“Entrepreneurship is about navigating prevailing conditions. Sometimes the right route is a detour. We are now commercializing the same technology platform already piloted at medical use for seed quality measurement. Our method has attracted broad international interest, with over one hundred contacts from more than 40 countries,” Ihme continues.
Funding Enables Market Entry in 2026
The EU funding granted by the ELY Centre enables commercialization and the launch of international market activities. The new product is scheduled to be launched in 2026. The global seed trade represents a market worth hundreds of billions of euros.
“This funding significantly accelerates our transition from research to commercial growth. We are building technology that serves both healthcare and the bioeconomy ecosystem—based on Finnish top-level expertise. Now is the right moment to accelerate our international breakthrough,” Ihme concludes.